Senores Pharmaceuticals Limited (NSEI: SENORES)
Health Care · Pharmaceuticals · IN
Rs1,477.70
+3.90% today · +112.1% 1Y
Senores Pharmaceuticals Limited (NSEI: SENORES) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $711.69M and employs 194 people.
Over the last twelve months the share price has gained 112.1%, trading between 632.05 and 1.51K.
Tweenvest scores Senores Pharmaceuticals Limited across four factors: quality 60/100, value 21/100. Its strongest factor is quality.
SENORES price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $711.69M
- Revenue (TTM)
- $71.95M
- P/E
- 52.22
- EPS
- 28.30
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- Rs1,509.80
- 52-week low
- Rs632.05
- Avg volume (3M)
- —
- Shares outstanding
- 46.05M
- Employees
- 194
- Next earnings
- —
About Senores Pharmaceuticals Limited
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches markets across India, the United States, the United Kingdom, Canada, and other international territories. The company specializes in a diverse array of therapeutic solutions, encompassing analgesics/antipyretics, anesthetics, antibacterials, antivirals, antifungals, antioxidants, antineoplastics, blood-related therapies, cardiovascular and neurological medications, antacids, and vitamin and mineral supplements. Additionally, Senores offers a selection of generic drugs targeting pain, inflammation, fever, diabetes, malaria, and urinary tract conditions, as well as neutral supplements. Complementing its product offerings, the firm also provides management and consultancy services.
- ISIN
- INE0RB801010
- Founded
- 2017
- Listed since
- Dec 30, 2024
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.16 | +0.12% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.15 | +0.00% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.34 | -0.07% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.70 | -0.03% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.52 | -0.99% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.